Lundbeck’s focus on the U.S. is paying off. And it’s a good thing, too. While revenue in its native Europe slid by one-fourth in the first half of this year, U.S. sales drove the Danish drugmaker to 5% sales growth overall.
The FDA is warning about potentially fatal skin reactions tied to Eli Lilly’s antipsychotic Zyprexa (olanzapine). The news deals some unfavorable cards to Lilly as it competes in a crowded long-acting injectables market.